-

Verge Genomics to Present at 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023

SAN FRANCISCO--(BUSINESS WIRE)--Verge Genomics, a clinical-stage, tech-enabled biotechnology company pioneering the use of artificial intelligence (AI) and human data to transform drug discovery, announced that Alice Zhang, CEO and co-founder of Verge Genomics, will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023 at 11:30 AM (PT).

Onsite:

Presentation: Thursday, January 12
Where: Mission Bay (32nd floor), The Westin St. Francis, San Francisco
Time: 11:30 AM - 11:55 AM (PT)
Presenter: Alice Zhang, CEO and co-founder, Verge Genomics

About Verge Genomics

Verge uses AI and human data to develop better drugs faster for the most challenging diseases of our generation. Verge has built CONVERGE™, an end-to-end drug discovery and development platform, that integrates multiple technological innovations from discovery to translation to streamline drug development. Its pioneering use of the industry’s most advanced all-in-human, AI-powered drug discovery platform identifies new medicines more efficiently and with an improved probability of success.

Verge is one of the first AI-enabled drug discovery companies to independently develop a clinical candidate from a novel target discovered from its platform. Verge has further demonstrated the power of CONVERGE™ by delivering a broad pipeline spanning diverse therapeutic areas, with its first program, an investigational PIKfyve inhibitor for the treatment of ALS, now in the clinic. The company is led by experienced drug developers and computational biologists with a shared belief that technology has created a new opportunity to deliver life-changing medicines more efficiently.

For additional information, please visit VergeGenomics.com. Follow us on LinkedIn and Twitter.

Contacts

Verge Genomics
Adam Silverstein
Scient PR
adam@scientpr.com

Verge Genomics


Release Versions
Hashtags

Contacts

Verge Genomics
Adam Silverstein
Scient PR
adam@scientpr.com

Social Media Profiles
More News From Verge Genomics

Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Verge Genomics, a clinical-stage biotechnology company transforming drug discovery using artificial intelligence and human data, today announced the completion of the Phase 1 clinical trial of VRG50635 in healthy adult volunteers. VRG50635 was dosed up to the maximum single and repeated doses planned, demonstrating a favorable safety, tolerability, and pharmacokinetic profile supportive of advancement into a proof-of-concept study in people with amy...

Verge Genomics to Present at Mass General Brigham & Bank of America World Medical Innovation Forum

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Verge Genomics, a clinical-stage, biotechnology company pioneering the use of artificial intelligence (AI) and human data to transform drug discovery, announced today that Robert H. Scannevin, Ph.D., Chief Scientific Officer, will join other experts in a panel discussion regarding the latest trends in brain health, at the Mass General Brigham and Bank of America World Medical Innovation Forum in Boston on June 12, 2023. Details of the Panel are as f...

Verge Genomics to Incorporate Emerald Digital Health Technology into its ALS Phase 1b Proof-of-Concept Clinical Trial

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Verge Genomics, a clinical-stage, tech-enabled biotechnology company pioneering the use of artificial intelligence (AI) and human data to transform drug discovery and development, announced that Emerald Innovations’ wireless digital health technology will be used to capture critical patient data in its planned Phase 1b proof-of-concept study of the PIKfyve inhibitor VRG50635, a novel therapeutic in clinical development for amyotrophic lateral sclero...
Back to Newsroom